All articles
Zepbound® for Weight Loss: Dosage, Pricing & More
Reading time:
5 min
Weight loss
Get expert guidance and a personalized care plan designed around you.
Is Zepbound® Safe for Weight Loss?
Safety is a primary concern when considering any weight loss supplement. Zepbound® is generally considered safe for any user meeting the above-specified requirements. However, be aware of the precautions and risks outlined in the prescribing information for Zepbound®, which are summarized below:
Potential Side Effects
Gastrointestinal Issues: The most commonly reported side effects from users of Zepbound® include nausea, vomiting, diarrhea, constipation, and/or stomach upset. (1,2) Your provider will work with you to create a personalized dosing schedule with this in mind. Users generally start at the lowest dose and slowly increase to the maximum dose over a span of months to minimize the likelihood of experiencing unpleasant gastrointestinal side effects. It’s important to note that most gastrointestinal side effects are generally mild to moderate and go away in time after your body has gotten used to the medication. (1,2)
Thyroid C-cell Tumors: Animal studies have shown a risk of thyroid tumors and cancer in rodents, but the relevance to humans is still unclear. (2)
Hypersensitivity Reactions: Rare cases of severe allergic reactions have been reported. (2)
Safety Precautions
Consult a Healthcare Provider: Always consult with a healthcare provider before starting Zepbound®, especially if you have a history of thyroid problems or other medical conditions.
Monitor for Side Effects: Be vigilant about any adverse reactions and report them to your doctor immediately, as they may decrease your dose or take you off Zepbound® altogether. While highly unlikely, be sure to notify your provider if you notice a lump or swelling in your neck, experience hoarseness, have difficulty swallowing, or encounter shortness of breath, as these could indicate symptoms of thyroid cancer. (2)
Getting Started on Zepbound® for Weight Loss
Zepbound® offers a promising solution for those looking to achieve effective weight loss. Its ability to reduce appetite, improve insulin sensitivity, and promote fat loss makes it a valuable tool in weight management. However, it is essential to use it safely and under the guidance of a healthcare provider.
Ready to take the next step in your weight loss journey? Find out if you’re eligible for our program to learn how Zepbound® or other GLP-1 medications can help you reach your goals.
With personalized care, direct medical access, and consistent support, Mochi Health is committed to your weight loss success. Explore how our physician-crafted program can help you achieve lasting results.
References:
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
Highlights of Prescribing Information - Zepbound® (Tirzepatide) Injection. Access Data FDA, Food and Drug Administration, Nov. 2023, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
Willard, F. S., Douros, J. D., Gabe, M. B., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J., Stutsman, C., Cardona, G. R., Urva, S., Emmerson, P. J., Holst, J. J., D'Alessio, D. A., Coghlan, M. P., Rosenkilde, M. M., Campbell, J. E., & Sloop, K. W. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI insight, 5(17), e140532. https://doi.org/10.1172/jci.insight.140532
Urva, S., Coskun, T., Loghin, C., Cui, X., Beebe, E., O'Farrell, L., Briere, D. A., Benson, C., Nauck, M. A., & Haupt, A. (2020). The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes, obesity & metabolism, 22(10), 1886–1891. https://doi.org/10.1111/dom.14110
Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., Ahmad, N. N., & Forrester, T. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature medicine, 29(11), 2909–2918. https://www.nature.com/articles/s41591-023-02597-w
This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.
Share this post
Weight loss
More articles
Read next
For iOS & Android
